NEXTCURE INC (NXTC)
US65343E1082 - Common Stock
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
NextCure, Inc. (Nasdaq: NXTC) will present phase 1b data of NC410 in combination with pembrolizumab at ASCO 2024. ...
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74...
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering...
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
BELTSVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering...
Wall Street’s Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich
The market is surging higher after dovish Fed comments. Here are seven of Wall Street’s favorite penny stocks that can help make you rich
NXTC Stock Earnings: NextCure Beats EPS for Q4 2023
NXTC stock results show that NextCure beat analyst estimates for earnings per share the fourth quarter of 2023.
NXTC Stock Earnings: NextCure Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips NextCure (NASDAQ:NXTC) just reported results for the fourth quarter of 2023.Nex...
NextCure Provides Business Update and Reports Full Year 2023 Financial Results
NextCure Provides Business Update and Reports Full Year 2023 Financial Results
Prioritizing and focusing on highest-value opportunities NC410 (ovarian and CRC) and LNCB74 (B7-H4 ADC)Based on early evidence of clinical activity with...
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
BELTSVILLE, Md., March 05, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering...
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
BELTSVILLE, Md., Jan. 18, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
BELTSVILLE, Md., Dec. 21, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...
NextCure stock falls 20% amid program shutdown, business update (NASDAQ:NXTC)
NextCure (NXTC) stock fell nearly 20% Thursday following news that it was shifting resources from its drug candidate NC762 to its antibody drug conjugate program. Read more here.
NextCure Provides Year-End Clinical Pipeline Updates
NextCure Provides Year-End Clinical Pipeline Updates
BELTSVILLE, Md., Dec. 14, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...
NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference
NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference
BELTSVILLE, Md., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...
NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML
New publication in Journal of Clinical Investigation provides compelling evidence for NC525’s ability to specifically kill leukemic cells while sparing...
NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results
NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results
Phase 1b updates for NC410 and NC762, and operational update for NC525 Phase 1a are expected by year endCash of approximately $118 million expected to fund...
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)
Data Presented at the 2023 American Society for Bone and Mineral Research (ASBMR) Annual Meeting
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)
Data Presented at the 2023 American Society for Bone and Mineral Research (ASBMR) Annual Meeting...
NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease
BELTSVILLE, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, including neuroinflammatory disease, today announced the presentation of preclinical data relating to NC181, a novel humanized antibody targeting ApoE4, for the treatment of Alzheimer’s disease (AD), at the 2nd Annual Neurodegeneration Targets, Drug Discovery for Progressive Central Nervous System Disorders conference.